Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen specific immunoglobulin E production in mice

Biol Pharm Bull. 2005 Aug;28(8):1462-6. doi: 10.1248/bpb.28.1462.

Abstract

Recent studies have suggested that oral bacteriotherapy with probiotics might be useful in the management of allergic diseases. We investigated the effect of oral administration of Bifidobacterium bifidum G9-1 (BBG9-1) on immunoglobulin (Ig) E production in BALB/c mice. Live BBG9-1 was orally administered to mice for 2 weeks from 1 week before ovalbumin (OVA)-immunization. The treatment of BBG9-1 significantly reduced serum total IgE level. In addition, BBG9-1 significantly and largely reduced the serum level of OVA-specific IgE without lowering of the specific IgG1 and increasing of the specific IgG2a. We also examined T helper type (Th) 1 and Th2 cytokine production from OVA-immunized splenocytes by restimulation with OVA in vitro. Productions of interferon (IFN)-gamma, interleukin (IL)-4 and IL-5 from the splenocytes of mice given BBG9-1 were weaker than those of control mice. We conclude that oral administration of BBG9-1 selectively and powerfully suppresses total and antigen specific IgE production in mice. It is suggested that BBG9-1 is useful for the prophylactic treatment in IgE-dependent allergic diseases.

MeSH terms

  • Administration, Oral
  • Animals
  • Bifidobacterium*
  • Enzyme-Linked Immunosorbent Assay
  • Immunoglobulin E / biosynthesis*
  • Interferon-gamma / biosynthesis
  • Interleukins / biosynthesis
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Ovalbumin / blood
  • Spleen / cytology
  • Spleen / metabolism

Substances

  • Interleukins
  • Immunoglobulin E
  • Interferon-gamma
  • Ovalbumin